Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Dami Collier
HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Author Correction: SARS-CoV-2 evolution during treatment of chronic infection - Nature
Correction to: Nature https://doi.org/10.1038/s41586-021-03291-yPublished online 5 February 2021 In the version of this article initially published, the surname of a member of The COVID-19 Genomics UK (COG-UK) Consortium was misspelt as Gramatopoulos. The correct spelling is Dimitris Grammatopoulos. The name has been corrected in the HTML and PDF versions of the article. Author information Author notes These authors contributed equally: Steven A. Kemp, Dami A. Collier, Rawlings P.
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 - Nature
Abstract Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age1. Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccine2 in elderly participants and younger healthcare workers.
SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough
Petra Mlcochova, Steven Kemp, Mahesh Shanker Dhar, Guido Papa, Bo Meng, Swapnil Mishra, Charlie Whittaker, Thomas Mellan, Isabella Ferreira, Rawlings Datir, Dami A.
Age-related heterogeneity in neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination
Dami A. Collier, Isabella A.T.M. Ferreira, Rawlings Datir, Bo Meng, Laura Bergamaschi, The CITIID-NIHR BioResource COVID-19 Collaboration, Anne Elmer, Nathalie Kingston, Barbara Graves, Kenneth GC Smith, John R. Bradley, Paul A. Lyons, Lourdes Ceron-Gutierrez, Gabriela Barcenas-Morales, Rainer Doffinger, Mark Wills, View ORCID ProfileRavindra K. Gupta doi: https://doi.org/10.1101/2021.02.03.21251054 Abstract Background Vaccines remain the cornerstone for containing the SARS-CoV-2 pandemic.
SARS-CoV-2 evolution during treatment of chronic infection - Nature
Abstract The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for virus infection through the engagement of the human ACE2 protein1 and is a major antibody target.
SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
Abstract SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2.
Active and passive case-finding in tuberculosis-affected households in Peru: a 10-year prospective cohort study
Summary Background Active case-finding among contacts of patients with tuberculosis is a global health priority, but the effects of active versus passive case-finding are poorly characterised. We assessed the contribution of active versus passive case-finding to tuberculosis detection among contacts and compared sex and disease characteristics between contacts diagnosed through these strategies.
Virological efficacy of PI monotherapy for HIV-1 in clinical practice
Background Clinical trials of PI monotherapy indicate that most participants maintain viral suppression and emergent protease resistance is rare. However, outcomes among patients receiving PI monotherapy for clinical reasons, such as toxicity or adherence issues, are less well studied.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Dami
Contact Dami, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack